RMTI
Rockwell Medical Inc
$
0.986
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.015
Open
1.000
VWAP
0.99
Vol
717.40K
Mkt Cap
33.93M
Low
0.9649
Amount
707.96K
EV/EBITDA(TTM)
18.93
Total Shares
30.32M
EV
25.80M
EV/OCF(TTM)
7.38
P/S(TTM)
0.37
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
16.24M
-42.64%
-0.045
-190%
17.15M
-30.48%
-0.045
+125%
18.35M
-2.99%
-0.040
-0%
Estimates Revision
The market is revising Upward the revenue expectations for Rockwell Medical, Inc. (RMTI) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by 4.39%.
Revenue Estimates for FY2025
Revise Upward
+0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-2.78%
In Past 3 Month
Stock Price
Go Up
+4.39%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast RMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RMTI is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.986
Low
3.00
Averages
4.00
High
5.00
Current: 0.986
Low
3.00
Averages
4.00
High
5.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$7 → $3
2025-03-24
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$7 → $3
2025-03-24
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$7
2024-12-23
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$7
2024-12-23
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$9 → $7
2024-11-25
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$9 → $7
2024-11-25
Maintains
Strong Buy
Reason
Rodman & Renshaw
Brandon Folkes
Strong Buy
Initiates
$5
2024-11-14
Reason
Rodman & Renshaw
Brandon Folkes
Price Target
$5
2024-11-14
Initiates
Strong Buy
Reason
Rodman & Renshaw initiated coverage of Rockwell Medical with a Buy rating and $5 price target. Rockwell has been a leading provider of dialysis concentrates in the U.S. for over 20 years, supplying essential concentrates used in dialysis machines to help patients with kidney issues, the analyst tells investors in a research note. The firm says that with expected revenue of over $65M in 2025 and potential for further gross margin improvement, the company remains undervalued despite the challenges of heavy customer concentration risk.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Rockwell Medical Inc (RMTI.O) is -5.97, compared to its 5-year average forward P/E of 0.04. For a more detailed relative valuation and DCF analysis to assess Rockwell Medical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.04
Current PE
-5.97
Overvalued PE
63.19
Undervalued PE
-63.12
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.14
Current EV/EBITDA
-21.67
Overvalued EV/EBITDA
10.68
Undervalued EV/EBITDA
-10.97
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
0.66
Current PS
0.99
Overvalued PS
1.07
Undervalued PS
0.24
Financials
Annual
Quarterly
FY2025Q2
YoY :
-37.79%
16.07M
Total Revenue
FY2025Q2
YoY :
-361.94%
-1.35M
Operating Profit
FY2025Q2
YoY :
-534.99%
-1.49M
Net Income after Tax
FY2025Q2
YoY :
-500.00%
-0.04
EPS - Diluted
FY2025Q2
YoY :
+45.33%
1.68M
Free Cash Flow
FY2025Q2
YoY :
-11.58%
15.57
Gross Profit Margin - %
FY2025Q2
YoY :
-116.37%
3.05
FCF Margin - %
FY2025Q2
YoY :
-797.74%
-9.28
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.1K
USD
4
3-6
Months
8.8K
USD
3
6-9
Months
11.6K
USD
3
0-12
Months
6.5K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
94.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.1K
USD
4
3-6
Months
8.8K
USD
3
6-9
Months
11.6K
USD
3
0-12
Months
6.5K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
94.0K
USD
Months
0-12
0
0.0
USD
Months
RMTI News & Events
Events Timeline
2025-07-08 (ET)
2025-07-08
06:03:13
Rockwell Medical and Innovative Renal Care sign three-year partnership agreement
2025-03-20 (ET)
2025-03-20
06:05:34
Rockwell Medical sees 2025 revenue $65..0M-$70.0M vs. $101.5M in 2024
2025-03-20
06:03:01
Rockwell Medical reports Q4 adjusted EPS 4c, consensus 2c
Sign Up For More Events
Sign Up For More Events
News
2.0
10-23NewsfilterRockwell Medical Recognized as One of Fortune's 'Best Workplaces in Manufacturing & Production' for the Second Consecutive Year
5.0
09-30SeekingAlphaRockwell Medical elevates Heather Hunter to Chief Operating Officer
4.0
09-29NASDAQ.COMEverything You Should Know About Rockwell Medical's (RMTI) Upgrade to Buy Rating
Sign Up For More News
People Also Watch
FAQ
What is Rockwell Medical Inc (RMTI) stock price today?
The current price of RMTI is 0.9855 USD — it has decreased -2.38 % in the last trading day.
What is Rockwell Medical Inc (RMTI)'s business?
What is the price predicton of RMTI Stock?
What is Rockwell Medical Inc (RMTI)'s revenue for the last quarter?
What is Rockwell Medical Inc (RMTI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Rockwell Medical Inc (RMTI)'s fundamentals?
How many employees does Rockwell Medical Inc (RMTI). have?